NCT00241007已完成3 期
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 836
- 试验地点
- 2
- 主要终点
- Adverse events and serious adverse events at each study visit for 54 weeks
研究概览
简要总结
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •SUCCESSFUL COMPLETION OF STUDY CVAH631C2301
排除标准
- 未提供
结局指标
主要结局
Adverse events and serious adverse events at each study visit for 54 weeks
次要结局
- Change from baseline in diastolic blood pressure from baseline after 54 weeks
- Change from baseline in systolic blood pressure from baseline after 54 weeks
- Change from baseline in standing diastolic and systolic blood pressure after 54 weeks
- Hematology and blood chemistries up to 54 weeks
- Physical condition including pregnancy, pulse and weight at each study visit
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
The Drug-drug Interaction of SP2086 and ValsartanType 2 DiabetesNCT02815657Jiangsu HengRui Medicine Co., Ltd.16
已完成
3 期
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With HypertensionHypertensionNCT00446511Novartis Pharmaceuticals250
已完成
4 期
Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in HypertensionHypertensionNCT00400777Novartis460
已完成
3 期
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)HypertensionNCT00311740Novartis582
尚未招募
不适用
Bioequivalence study of Valsartan 160 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Karen Pharma and Food Supplement Co. Valsartan 160 mg tablet with brand Diovan® 160 mg tablet Novartis pharmaceuticals...IRCT20180620040164N18Karen Pharma and Food Supplement Co.24